Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRx-197 in plaque psoriasis
NCT00796211Phase 2Completed
- Sponsor
- CombinatoRx
- Start
- Nov 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CRx-197 in plaque psoriasis (5 arms), sponsored by CombinatoRx. Primary endpoint: Safety and tolerability at 6 weeks. Started Nov 2008; status: completed.
02
Drugs
CRx-197
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00796211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796211.